ArticleClinical transplantation2018
Impact of insurance type on eligibility for advanced heart failure therapies and survival.
Article in Clinical transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Barriers to prescribing and insurance approval of SGLT2 inhibitors for heart failure: a mixed-methods study in Jordan.Frontiers in pharmacology · 2026Article
- Changes in Heart Transplant Listings by Insurance and Race During the COVID Public Health Emergency.Circulation. Heart failure · 2025Observational
- Non-Medical Characteristics Affect Referral for Advanced Heart Failure Services: a Retrospective Review.Journal of racial and ethnic health disparities · 2025Article
- Lifting the Veil on Advanced Heart Failure.JACC. Heart failure · 2023Article
- The impact of race on utilization of durable left ventricular assist device therapy in patients with advanced heart failure.Journal of cardiac surgery · 2022Article
- The effects of demographic, psychosocial, and socioeconomic characteristics on access to heart transplantation and left ventricular assist device.American heart journal plus : cardiology research and practice · 2022Article
- A scoping review of inequities in access to organ transplant in the United States.International journal for equity in health · 2022Article
- Article
- Exception Status Listing in the New Adult Heart Allocation System: A New Solution to an Old Problem?Circulation. Heart failure · 2021Article
- Insurance disparity in cardiovascular mortality among non-elderly cancer survivors.Cardio-oncology (London, England) · 2021Article
- Is the Affordable Care Act Medicaid Expansion Linked to Change in Rate of Ventricular Assist Device Implantation for Blacks and Whites?Circulation. Heart failure · 2020Article
- Different Lenses for the Same Story: Examining How Implicit Bias Can Lead Us to Different Clinical Decisions for the "Same" Patient.Journal of the American Heart Association · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMedicaid insurance in Georgia provides limited reimbursement for heart transplant (HT) and left ventricular assist devices (LVAD). We examined whether insurance type affects eligibility for and survival after receipt of HT or LVAD. METHODS AND
resultsWe retrospectively identified patients evaluated for HT/LVAD from 2012 to 2016. We used multivariable logistic and Cox proportional hazards regression to examine the association of insurance type on treatment eligibility and 1-year survival. Of 569 patients evaluated, 282 (49.6%) had private, 222 (39.0%) had Medicare, and 65 (11.4%) had Medicaid insurance. Patients with Medicaid were younger, more likely to be Black, with fewer medical comorbidities. In adjusted models, Medicare and Medicaid insurance predicted lower odds of eligibility for HT, but did not affect survival after HT. Among those ineligible for HT, Medicaid patients were less likely to receive destination therapy (DT) LVAD (adj OR 0.08, 95% CI 0.01-0.66; P = .02) and had increased risk of death (adj HR = 2.03, 95% CI 1.13-3.63; P = .01).
conclusionsDespite younger age and fewer comorbidities, patients with Medicaid insurance are less likely to receive DT LVAD and have an increased risk of death once deemed ineligible for HT. Medicaid patients in Georgia need improved access to DT LVAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.